BenzingaAugust 4, 2026 at 10:11 AM NYlast month
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Yahoo10 hours ago
Jim Cramer Thinks This Struggling Stock Could See A “Big Earnings Acceleration”
Yahoo2 hours ago
Walmart, Target, and Kroger face growing retail crime issue
Yahoo2 hours ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo5 hours ago
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run
Yahoo5 hours ago